ATC Group: J02AX Other antimycotics for systemic use

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J02AX in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J02 Antimycotics for systemic use
3 J02A Antimycotics for systemic use
4 J02AX Other antimycotics for systemic use

Group J02AX contents

Code Title
J02AX01 Flucytosine
J02AX04 Caspofungin
J02AX05 Micafungin
J02AX06 Anidulafungin
J02AX07
J02AX08

Active ingredients in J02AX

Active Ingredient

Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells.

Caspofungin acetate is a semi-synthetic lipopeptide (echinocandin) compound synthesised from a fermentation product of Glarea lozoyensis. Caspofungin acetate inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. Beta (1,3)-D-glucan is not present in mammalian cells.

Flucytosine is a fluorinated pyrimidine derivative. It is an antimycotic agent exerting fungistatic and fungicidal activity by interfering with protein and DNA synthesis. Fluorodeoxyuridine interferes with the enzyme thymidylate synthase. Inhibition of thymidylate synthase subsequently causes disruption of DNA synthesis.

Micafungin non-competitively inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall. 1,3-β-D-glucan is not present in mammalian cells. Micafungin exhibits fungicidal activity against most Candida species and prominently inhibits actively growing hyphae of Aspergillus species.

Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.).

Related product monographs

Document Type Information Source  
 Ancotil 2.5 g/250 ml Solution for Infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ANCOTIL Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 CANCIDAS Powder for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 ECALTA Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 ERAXIS Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 MYCAMINE Powder for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 REZZAYO Powder for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 REZZAYO Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)